Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
about
[Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studiesPretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysisNeutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer
P2860
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Prognostic utility of baseline ...... s: a review and meta-analysis.
@en
Prognostic utility of baseline ...... s: a review and meta-analysis.
@nl
type
label
Prognostic utility of baseline ...... s: a review and meta-analysis.
@en
Prognostic utility of baseline ...... s: a review and meta-analysis.
@nl
prefLabel
Prognostic utility of baseline ...... s: a review and meta-analysis.
@en
Prognostic utility of baseline ...... s: a review and meta-analysis.
@nl
P2860
P356
P1476
Prognostic utility of baseline ...... rs: a review and meta-analysis
@en
P2093
Danielle Benedict Sacdalan
Dennis Lee Sacdalan
P2860
P304
P356
10.2147/OTT.S153290
P407
P577
2018-02-23T00:00:00Z